Literature DB >> 21785578

Hemangiopericytoma of maxilla in a pediatric patient: a case report.

Rohit Anand1, Sonal Gupta.   

Abstract

The Hemangiopericytoma is a malignant vascular tumor arising from mesenchymal cells with pericytic differentiation. Hemangiopericytoma is most commonly seen in adults, and only 5% to 10% of cases occur in children. The tumor is extremely rare in the head and neck region (16%)1. Cytogenic abnormalities have been present in some hemangiopericytoma cases. Surgical resection remains the mainstay treatment. Adjuvant chemotherapy and radiotherapy is appropriate for cases of incomplete resections and life-threatening tumors particularly in children. Late relapses may occur and require long-term follow-up. A 4-year-old child patient with hemangiopericytoma of the maxilla presented with firm, recurrent, but painless jaw mass. Radiographic investigations revealed a poorly circumscribed radiolucency. The lesion biopsy showed well-circumscribed multiple lobules of tumor mass consisting of tightly packed, spindle-shaped cells. Chemotherapy and radiotherapy of the lesion was conducted. The role of the pediatric dental team is extensive in children with hemangiopericytoma, who require a regular dental review. The patient's oncologist should be immediately contacted if there is any suspicion of recurrence.

Entities:  

Keywords:  Chemotherapy; Hemangiopericytoma; Prognosis; Radiotherapy; Vascular tumor

Mesh:

Substances:

Year:  2010        PMID: 21785578      PMCID: PMC3140132     

Source DB:  PubMed          Journal:  J Dent Child (Chic)        ISSN: 1551-8949


  9 in total

1.  Cytogenetic abnormalities in a hemangiopericytoma of the spleen.

Authors:  Magnus Hallén; Luis A Parada; Ludmila Gorunova; Birger Pålsson; Michael Dictor; Bertil Johansson
Journal:  Cancer Genet Cytogenet       Date:  2002-07-01

Review 2.  Preoperative chemotherapy for congenital hemangiopericytoma and a review of the literature.

Authors:  M L del Rosario; A Saleh
Journal:  J Pediatr Hematol Oncol       Date:  1997 May-Jun       Impact factor: 1.289

3.  HEMANGIOPERICYTOMA: A VASCULAR TUMOR FEATURING ZIMMERMANN'S PERICYTES.

Authors:  A P Stout; M R Murray
Journal:  Ann Surg       Date:  1942-07       Impact factor: 12.969

Review 4.  Chemotherapy of malignant hemangiopericytoma.

Authors:  P P Wong; A Yagoda
Journal:  Cancer       Date:  1978-04       Impact factor: 6.860

5.  Hemangiopericytoma in pediatric ages: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group.

Authors:  A Ferrari; M Casanova; G Bisogno; A Mattke; C Meazza; A Gronchi; G Cecchetto; P Fidani; D Kunz; J Treuner; M Carli
Journal:  Cancer       Date:  2001-11-15       Impact factor: 6.860

Review 6.  Inflammatory myofibroblastic tumor in children: diagnosis and treatment.

Authors:  I Karnak; M E Senocak; A O Ciftci; M Cağlar; M Bingöl-Koloğlu; F C Tanyel; N Büyükpamukçu
Journal:  J Pediatr Surg       Date:  2001-06       Impact factor: 2.545

7.  Hemangiopericytoma: a 20-year single-institution experience.

Authors:  F R Spitz; M Bouvet; P W Pisters; R E Pollock; B W Feig
Journal:  Ann Surg Oncol       Date:  1998-06       Impact factor: 5.344

8.  Conventional hemangiopericytoma: modern analysis of outcome.

Authors:  N Joseph Espat; Jonathan J Lewis; Denis Leung; James M Woodruff; Christina R Antonescu; Jingu Shia; Murray F Brennan
Journal:  Cancer       Date:  2002-10-15       Impact factor: 6.860

9.  Hemangiopericytoma in infants and children. A report of six patients.

Authors:  J B Atkinson; G H Mahour; H Isaacs; J A Ortega
Journal:  Am J Surg       Date:  1984-09       Impact factor: 2.565

  9 in total
  2 in total

1.  Hemangiopericytoma of Gingiva in a 4-Year-Old Child: A Rare Case Report.

Authors:  Ashish Gupta; Sneha D Sharma; Pankaj Bansal; Seema Sikka
Journal:  J Maxillofac Oral Surg       Date:  2018-03-01

2.  Sinonasal hemangiopericytoma: A rare case report with review of literature.

Authors:  B V Shobha; B N Shivakumar; Santhosh Reddy; Neerav Dutta
Journal:  J Oral Maxillofac Pathol       Date:  2015 Jan-Apr
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.